Literature DB >> 23833125

Long-term statin use and risk of ductal and lobular breast cancer among women 55 to 74 years of age.

Jean A McDougall1, Kathleen E Malone, Janet R Daling, Kara L Cushing-Haugen, Peggy L Porter, Christopher I Li.   

Abstract

BACKGROUND: Mechanistic studies largely support the chemopreventive potential of statins. However, results of epidemiologic studies investigating statin use and breast cancer risk have been inconsistent and lacked the ability to evaluate long-term statin use.
METHODS: We used data from a population-based case-control study of breast cancer conducted in the Seattle-Puget Sound region to investigate the relationship between long-term statin use and breast cancer risk. Nine hundred sixteen invasive ductal carcinoma (IDC) and 1,068 invasive lobular carcinoma (ILC) cases in patients 55 to 74 years of age diagnosed between 2000 and 2008 were compared with 902 control women. All participants were interviewed in-person and data on hypercholesterolemia and all episodes of lipid-lowering medication use were collected through a structured questionnaire. We assessed the relationship between statin use and IDC and ILC risk using polytomous logistic regression.
RESULTS: Current users of statins for 10 years or longer had a 1.83-fold increased risk of IDC [95% confidence interval (CI): 1.14-2.93] and a 1.97-fold increased risk of ILC (95% CI: 1.25-3.12) compared with never users of statins. Among women diagnosed with hypercholesterolemia, current users of statins for 10 years or longer had more than double the risk of both IDC (OR: 2.04, 95% CI: 1.17-3.57) and ILC (OR: 2.43, 95% CI: 1.40-4.21) compared with never users.
CONCLUSION: In this contemporary population-based case-control study, long-term use of statins was associated with increased risks of both IDC and ILC. IMPACT: Additional studies with similarly high frequencies of statin use for various durations are needed to confirm this novel finding. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23833125      PMCID: PMC3770184          DOI: 10.1158/1055-9965.EPI-13-0414

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  37 in total

1.  Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase.

Authors:  S Rao; D C Porter; X Chen; T Herliczek; M Lowe; K Keyomarsi
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

2.  Random digit dialing in selecting a population-based control group.

Authors:  P Hartge; L A Brinton; J F Rosenthal; J I Cahill; R N Hoover; J Waksberg
Journal:  Am J Epidemiol       Date:  1984-12       Impact factor: 4.897

3.  Serum lipids, lipid-lowering drugs, and the risk of breast cancer.

Authors:  A Heather Eliassen; Graham A Colditz; Bernard Rosner; Walter C Willett; Susan E Hankinson
Journal:  Arch Intern Med       Date:  2005-10-24

4.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

5.  Cancer risk among statin users: a population-based cohort study.

Authors:  Søren Friis; Aslak H Poulsen; Søren P Johnsen; Joseph K McLaughlin; Jon P Fryzek; Susanne O Dalton; Henrik T Sørensen; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2005-04-20       Impact factor: 7.396

6.  Lovastatin 5-year safety and efficacy study. Lovastatin Study Groups I through IV.

Authors: 
Journal:  Arch Intern Med       Date:  1993-05-10

7.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

Review 8.  Carcinogenicity of lipid-lowering drugs.

Authors:  T B Newman; S B Hulley
Journal:  JAMA       Date:  1996-01-03       Impact factor: 56.272

9.  The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study.

Authors:  Denise M Boudreau; Jacqueline S Gardner; Kathleen E Malone; Susan R Heckbert; David K Blough; Janet R Daling
Journal:  Cancer       Date:  2004-06-01       Impact factor: 6.860

10.  Statin use and cancer risk in the General Practice Research Database.

Authors:  J A Kaye; H Jick
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more
  23 in total

1.  The association between metabolic health, obesity phenotype and the risk of breast cancer.

Authors:  Yong-Moon Mark Park; Alexandra J White; Hazel B Nichols; Katie M O'Brien; Clarice R Weinberg; Dale P Sandler
Journal:  Int J Cancer       Date:  2017-03-28       Impact factor: 7.396

Review 2.  The Hippo pathway, p53 and cholesterol.

Authors:  Yael Aylon; Moshe Oren
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

Review 3.  Statins and breast cancer prognosis: evidence and opportunities.

Authors:  Thomas P Ahern; Timothy L Lash; Per Damkier; Peer M Christiansen; Deirdre P Cronin-Fenton
Journal:  Lancet Oncol       Date:  2014-09       Impact factor: 41.316

Review 4.  Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.

Authors:  Behzad Yeganeh; Emilia Wiechec; Sudharsana R Ande; Pawan Sharma; Adel Rezaei Moghadam; Martin Post; Darren H Freed; Mohammad Hashemi; Shahla Shojaei; Amir A Zeki; Saeid Ghavami
Journal:  Pharmacol Ther       Date:  2014-02-26       Impact factor: 12.310

5.  Comparative safety of cardiovascular medication use and breast cancer outcomes among women with early stage breast cancer.

Authors:  Denise M Boudreau; Onchee Yu; Jessica Chubak; Heidi S Wirtz; Erin J Aiello Bowles; Monica Fujii; Diana S M Buist
Journal:  Breast Cancer Res Treat       Date:  2014-02-21       Impact factor: 4.872

6.  Lipid-lowering drugs, dyslipidemia, and breast cancer risk in a Medicare population.

Authors:  Catherine Schairer; D Michal Freedman; Shahinaz M Gadalla; Ruth M Pfeiffer
Journal:  Breast Cancer Res Treat       Date:  2018-02-15       Impact factor: 4.872

7.  Statin Use and Breast Cancer Risk in the Nurses' Health Study.

Authors:  Signe Borgquist; Rulla M Tamimi; Wendy Y Chen; Judy E Garber; A Heather Eliassen; Thomas P Ahern
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-01       Impact factor: 4.254

8.  Impact of cholesterol on disease progression.

Authors:  Chun-Jung Lin; Cheng-Kuo Lai; Min-Chuan Kao; Lii-Tzu Wu; U-Ging Lo; Li-Chiung Lin; Yu-An Chen; Ho Lin; Jer-Tsong Hsieh; Chih-Ho Lai; Chia-Der Lin
Journal:  Biomedicine (Taipei)       Date:  2015-06-01

9.  Altered gene expression in glycolysis-cholesterol synthesis axis correlates with outcome of triple-negative breast cancer.

Authors:  Peng-Cheng Zhong; Rong Shu; Hui-Wen Wu; Zhi-Wen Liu; Xiao-Ling Shen; Ying-Jie Hu
Journal:  Exp Biol Med (Maywood)       Date:  2020-11-27

Review 10.  Impact of cholesterol-pathways on breast cancer development, a metabolic landscape.

Authors:  Alina González-Ortiz; Octavio Galindo-Hernández; Gerson N Hernández-Acevedo; Gustavo Hurtado-Ureta; Victor García-González
Journal:  J Cancer       Date:  2021-05-19       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.